Does the media refer more to DFTX or CSTL?

In the previous week, Definium Therapeutics had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Definium Therapeutics and 4 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.84 beat Definium Therapeutics' score of 0.47 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Castle Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CSTL or PGNY?

In the previous week, Progyny had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 5 mentions for Progyny and 4 mentions for Castle Biosciences. Progyny's average media sentiment score of 1.18 beat Castle Biosciences' score of 0.84 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADUS or CSTL?

In the previous week, Castle Biosciences had 2 more articles in the media than Addus HomeCare. MarketBeat recorded 4 mentions for Castle Biosciences and 2 mentions for Addus HomeCare. Castle Biosciences' average media sentiment score of 0.84 beat Addus HomeCare's score of 0.79 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Castle Biosciences (CSTL) Competitors

$20.70 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$20.70 0.00 (0.00%)

As of 06/12/2026 05:34 PM Eastern

Compare

CSTL vs. HTFL, DFTX, PGNY, SGRY, and ADUS

Should you buy Castle Biosciences stock or one of its competitors? MarketBeat compares Castle Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Castle Biosciences include Heartflow (HTFL), Definium Therapeutics (DFTX), Progyny (PGNY), Surgery Partners (SGRY), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry.

How does Castle Biosciences compare to Heartflow?

Castle Biosciences (NASDAQ:CSTL) and Heartflow (NASDAQ:HTFL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Castle Biosciences has higher revenue and earnings than Heartflow. Castle Biosciences is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	1.82	-$24.16M	-$0.44	N/A
Heartflow	$176.03M	16.28	-$116.79M	-$3.11	N/A

Castle Biosciences has a net margin of -3.78% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Heartflow	-58.42%	N/A	-20.02%

In the previous week, Castle Biosciences had 2 more articles in the media than Heartflow. MarketBeat recorded 4 mentions for Castle Biosciences and 2 mentions for Heartflow. Castle Biosciences' average media sentiment score of 0.84 beat Heartflow's score of 0.44 indicating that Castle Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Castle Biosciences	Positive
Heartflow	Neutral

92.6% of Castle Biosciences shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 7.7% of Heartflow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Castle Biosciences presently has a consensus target price of $42.83, indicating a potential upside of 106.92%. Heartflow has a consensus target price of $37.00, indicating a potential upside of 11.31%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Castle Biosciences is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Castle Biosciences beats Heartflow on 11 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

In the previous week, Definium Therapeutics had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Definium Therapeutics and 4 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.84 beat Definium Therapeutics' score of 0.47 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Castle Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Castle Biosciences has higher revenue and earnings than Definium Therapeutics. Castle Biosciences is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Castle Biosciences	$344.23M	1.82	-$24.16M	-$0.44	N/A

Definium Therapeutics currently has a consensus price target of $37.92, suggesting a potential upside of 53.22%. Castle Biosciences has a consensus price target of $42.83, suggesting a potential upside of 106.92%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Definium Therapeutics has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Definium Therapeutics has a net margin of 0.00% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Summary

Castle Biosciences beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Progyny?

Castle Biosciences (NASDAQ:CSTL) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Progyny has a net margin of 5.23% compared to Castle Biosciences' net margin of -3.78%. Progyny's return on equity of 13.34% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Progyny	5.23%	13.34%	9.03%

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Progyny has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	1.82	-$24.16M	-$0.44	N/A
Progyny	$1.29B	1.62	$58.52M	$0.77	34.58

Castle Biosciences has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Progyny has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

In the previous week, Progyny had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 5 mentions for Progyny and 4 mentions for Castle Biosciences. Progyny's average media sentiment score of 1.18 beat Castle Biosciences' score of 0.84 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences presently has a consensus target price of $42.83, suggesting a potential upside of 106.92%. Progyny has a consensus target price of $29.67, suggesting a potential upside of 11.40%. Given Castle Biosciences' higher probable upside, equities analysts clearly believe Castle Biosciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Progyny beats Castle Biosciences on 13 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Surgery Partners?

Castle Biosciences (NASDAQ:CSTL) and Surgery Partners (NASDAQ:SGRY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Castle Biosciences has higher earnings, but lower revenue than Surgery Partners. Castle Biosciences is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	1.82	-$24.16M	-$0.44	N/A
Surgery Partners	$3.31B	0.61	-$77.90M	-$0.60	N/A

Castle Biosciences presently has a consensus price target of $42.83, indicating a potential upside of 106.92%. Surgery Partners has a consensus price target of $22.18, indicating a potential upside of 44.88%. Given Castle Biosciences' higher possible upside, equities research analysts clearly believe Castle Biosciences is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Surgery Partners	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Castle Biosciences has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Surgery Partners has a net margin of -2.28% compared to Castle Biosciences' net margin of -3.78%. Surgery Partners' return on equity of 1.04% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Surgery Partners	-2.28%	1.04%	0.41%

92.6% of Castle Biosciences shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 2.0% of Surgery Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Castle Biosciences had 3 more articles in the media than Surgery Partners. MarketBeat recorded 4 mentions for Castle Biosciences and 1 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.87 beat Castle Biosciences' score of 0.84 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Castle Biosciences	Positive
Surgery Partners	Very Positive

Summary

Surgery Partners beats Castle Biosciences on 10 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Castle Biosciences had 2 more articles in the media than Addus HomeCare. MarketBeat recorded 4 mentions for Castle Biosciences and 2 mentions for Addus HomeCare. Castle Biosciences' average media sentiment score of 0.84 beat Addus HomeCare's score of 0.79 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.4% of Addus HomeCare shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 4.1% of Addus HomeCare shares are owned by company insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Addus HomeCare has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Addus HomeCare has a net margin of 6.89% compared to Castle Biosciences' net margin of -3.78%. Addus HomeCare's return on equity of 9.80% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Addus HomeCare currently has a consensus target price of $131.00, indicating a potential upside of 40.44%. Castle Biosciences has a consensus target price of $42.83, indicating a potential upside of 106.92%. Given Castle Biosciences' higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Addus HomeCare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.22	$95.91M	$5.41	17.24
Castle Biosciences	$344.23M	1.82	-$24.16M	-$0.44	N/A

Summary

Addus HomeCare beats Castle Biosciences on 10 of the 17 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$627.83M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-47.05	20.00	24.00	24.42
Price / Sales	1.82	303.98	516.42	110.81
Price / Cash	18.59	53.61	27.48	37.92
Price / Book	1.28	8.32	10.74	6.82
Net Income	-$24.16M	$23.94M	$3.57B	$337.56M
7 Day Performance	2.88%	1.84%	0.58%	1.16%
1 Month Performance	8.21%	-0.04%	1.48%	3.16%
1 Year Performance	10.40%	44.82%	25.41%	30.60%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSTL Castle Biosciences	3.1908 of 5 stars	$20.70 flat	$42.83 +106.9%	+10.4%	$627.83M	$344.23M	N/A	540
HTFL Heartflow	2.1412 of 5 stars	$28.61 +0.5%	$37.00 +29.3%	N/A	$2.45B	$191.42M	N/A	699	Insider Trade Gap Down
DFTX Definium Therapeutics	2.994 of 5 stars	$21.93 -4.7%	$37.92 +72.9%	+245.2%	$2.19B	N/A	N/A	40	Options Volume
PGNY Progyny	4.1753 of 5 stars	$25.98 +0.2%	$29.67 +14.2%	+26.6%	$2.03B	$1.29B	33.71	310	Positive News Gap Down
SGRY Surgery Partners	4.0569 of 5 stars	$13.83 -0.1%	$22.18 +60.4%	-32.7%	$1.81B	$3.31B	N/A	16,000	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. HTFL, DFTX, PGNY, SGRY, and ADUS

How does Castle Biosciences compare to Heartflow?

Summary

How does Castle Biosciences compare to Definium Therapeutics?

Summary

How does Castle Biosciences compare to Progyny?

Summary

How does Castle Biosciences compare to Surgery Partners?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. HTFL, DFTX, PGNY, SGRY, and ADUS

How does Castle Biosciences compare to Heartflow?

Which has stronger earnings & valuation, CSTL or HTFL?

Is CSTL or HTFL more profitable?

Does the media favor CSTL or HTFL?

Do insiders & institutionals believe in CSTL or HTFL?

Do analysts rate CSTL or HTFL?

Summary

How does Castle Biosciences compare to Definium Therapeutics?

Does the media refer more to DFTX or CSTL?

Do insiders & institutionals hold more shares of DFTX or CSTL?

Which has higher earnings and valuation, DFTX or CSTL?

Do analysts prefer DFTX or CSTL?

Which has more risk & volatility, DFTX or CSTL?

Is DFTX or CSTL more profitable?

Summary

How does Castle Biosciences compare to Progyny?

Is CSTL or PGNY more profitable?

Do institutionals and insiders have more ownership in CSTL or PGNY?

Which has better earnings and valuation, CSTL or PGNY?

Which has more risk & volatility, CSTL or PGNY?

Does the media prefer CSTL or PGNY?

Do analysts recommend CSTL or PGNY?

Summary

How does Castle Biosciences compare to Surgery Partners?

Which has stronger earnings & valuation, CSTL or SGRY?

Do analysts prefer CSTL or SGRY?

Which has more volatility & risk, CSTL or SGRY?

Is CSTL or SGRY more profitable?

Do insiders & institutionals believe in CSTL or SGRY?

Does the media favor CSTL or SGRY?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Does the media prefer ADUS or CSTL?

Do insiders & institutionals have more ownership in ADUS or CSTL?

Which has more volatility & risk, ADUS or CSTL?

Is ADUS or CSTL more profitable?

Do analysts prefer ADUS or CSTL?

Which has better earnings & valuation, ADUS or CSTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools